Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Impact of sequencing of CART vs bi-specific antibody on survival in relapsed/refractory large B-cell lymphoma: An analysis from the ABC consortium

View Full Paper
Ask AI
Bookmark
Share

Authors

CTColin ThomasYTYun Kyoung TigerLFLindsey Fitzgerald

Discussion

Loading...

Member takes

Overview

Analysis shows response rates and survival in large B-cell lymphoma may differ based on treatment sequencing and prior therapies.

Key Points

  • Survival outcomes vary based on sequencing of bi-specific antibody and CART in large B-cell lymphoma.
  • Response rates and progression free survival do not significantly differ between treatment sequences.
  • Assessment of treatment sequencing revealed no significant differences in overall survival or efficacy metrics.
  • Stratification of patients based on treatment revealed important insights into performance status and therapy sequencing.

Cite This Study

Thomas et al. (2025) studied this question.

synapsesocial.com/papers/69362f484fa91c937236d744https://doi.org/10.1182/blood-2025-398
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Real world outcomes of sequencing bispecific antibodies (BsAb) in patients with relapsed / refractory follicular lymphoma (R/R FL): A multi-center cohort study from cubic consortium2025
  2. 2Large B-cell lymphoma following CD19-directed CART-cell therapy failure: Impact of CAR construct on disease features and outcomes of subsequent therapies2025
  3. 3Sequencing CD20-directed bispecific antibody and CD19-directed CAR T cell therapy in large B cell lymphoma: A multicenter real-world study2025
  4. 4Outcomes of patients (Pts) with relapsed/refractory (R/R) large B-cell lymphoma (LBCL) progressing after CD3xCD20 bispecific antibody (BsAb) therapy: A new unmet need2025
  5. 5Outcomes of CD20xCD3 bispecific antibody therapy in adult patients with Relapsed/Refractory transformed indolent lymphoma2025